home > drugs a-z list > eraxis (anidulafungin) drug center > eraxis (anidulafungin) drug - overdosage and contraindications

During clinical trials a single 400 mg dose of ERAXIS (anidulafungin) was inadvertently administered as a loading dose. No clinical adverse events were reported. In a study of 10 healthy subjects administered a loading dose of 260 mg followed by 130 mg daily, ERAXIS (anidulafungin) was generally well tolerated; 3 of the 10 subjects experienced transient, asymptomatic transaminase elevations ( ≤ 3 x ULN).

Anidulafungin is not dialyzable.

The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50 mg/day) or equivalent to 5 times the recommended daily dose for candidemia and other Candida infections (100 mg/day), based on relative body surface area comparison.

ERAXIS (anidulafungin) is contraindicated in persons with known hypersensitivity to anidulafungin, any component of ERAXIS (anidulafungin) , or other echinocandins.

Last reviewed on RxList: 12/9/2010
This monograph has been modified to include the generic and brand name in many instances.